Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...